

**Information for the Financial Press**

**PULSION AG: Annual Shareholders' Meeting**

**Management Board confirms EBIT forecast of EUR 5.1 million for the year 2008 / Approval of all agenda items**

Munich, May 08, 2008 – PULSION Medical Systems AG, a life sciences corporation listed on the Prime Standard in Frankfurt that specializes in intelligent medical diagnosis and therapy systems, held its annual shareholders' meeting for the financial year 2007 in Munich today. Approximately 61.9% of the share capital was present. All motions were approved by majorities beyond 99%.

The management board presented in its report to the shareholders the successful development of the company for the previous financial year and explained the company's strategy to improve market penetration of the PULSION product lines – particularly in the USA. Furthermore a summary of the necessary changes to the sales and marketing structure to further speed up the growth in the coming years was given. Despite of the moderate EBIT growth of 7% in the first three months, the forecast for 2008 of at least EUR 5.1 million has been confirmed.

“In 2007, we showed once again good progress with our business model and lifted profitability to a competitive level. We are going to bring our organization into alignment for a successful future“, said Bradley P. Gould, CEO of PULSION.

The presentation of the management board as well as additional information concerning the annual shareholders' meeting is available on the company's website.

# PULSION

Medical Systems

## **About PULSION:**

PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals.

The business unit *PULSION Critical Care* covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients.

Products and activities of the business unit *PULSION Pharma* are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology.

PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines.

Further information about PULSION is available at [www.pulsion.com](http://www.pulsion.com).

## **PULSION Medical Systems AG**

**ISIN DE0005487904**

**Equity capital: Euro 9,577,302 divided into no-par-value euro 1 individual share certificates**

---

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of PULSION Medical Systems AG as of the date of this release. These forward looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. PULSION Medical Systems AG disclaims any intent or obligation to update any of these forward-looking statements.

---

## **Contacts:**

PULSION Medical Systems AG  
Christian Steiner, MD  
Director Corporate Marketing  
Tel.: +49 (0)89 / 459914 200  
Fax: +49 (0)89 / 459914 208  
E-mail: [steiner@pulsion.com](mailto:steiner@pulsion.com)